Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration

US5733871A · kind A · utility

Assignee

• The General Hospital Corporation · US

Inventors

• Brian J. Alps · Linlithgow, GB
• Christine Brown · Glasgow, GB
• Franklin D. Collins · Boulder, US
• Caroline J. Emmett · Belmont, US
• Michael Spedding · Paris, FR
• Deborah A. Russell · Thousand Oaks, US
• Seth Finklestein · Needham, US
• Michael A. Moskowitz · Belmont, US
• Roger Whiting · Los Altos, US

Key dates

• Filing date: Mar 16, 1995
• Grant date: Mar 31, 1998
• Expiry date: Mar 16, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/1825
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Intravenous administration and pharmaceutically acceptable compositions of neurotrophic factors for treating neuronal damage in the central nervous system of individuals in need of such treatment are disclosed. The neuronal damage associated with ischemia, hypoxia, or neurodegeneration may result from stroke or cardiac arrest. This invention provides for the intravenous administration of neurotrophic factors such as bFGF, aFGF, NGF, CNTF, BDNF, NT3, NT4, IGF-I and IGF-II.